Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Samsung Medical Center

Status and phase: Completed; Phase 3

Conditions: Crohn's Disease

Treatments: Drug: Infliximab

Study type: Interventional

Funder types: Other

Identifiers

NCT01661257

2009-10-038-002

Details and patient eligibility

About

This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.

Full description

The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the treatment have not yet been investigated.

Enrollment: 20 patients

Sex: All

Ages: 13 to 17 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• •Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment

  • confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings

Exclusion criteria

• •patients who has proven to have infliximab antibody

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

TIM-3

Experimental group

Description:

T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.

Treatment:

Drug: Infliximab